___________________________________________________________________________ Colorectal Cancer 30. Rose DP, Boyar AP, Wynder EL. International comparisons of mortality rates for cancer of the breast, ovary, prostate, and colon, and per capita food consumption. Cancer . 1986;58(11):2363-2371. 31. Reddy BS. Dietary fat and its relationship to large bowel cancer. Cancer Res . 1981;41(9 Pt 2):3700-3705. 32. Potter JD, McMichael AJ. Diet and cancer of the colon and rectum: a case-control study. J Natl Cancer Inst . 1986;76(4):557-569. 33. Bingham SA. Diet and large bowel cancer. J R Soc Med . 1990;83(7):420-422. 34. Augustsson K, Skog K, Jägerstad M, Dickman PW, Steineck G. Dietary heterocyclic amines and cancer of the colon, rectum, bladder, and kidney: a population-based study. Lancet . 1999;353(9154):703-707. 35. Forman D. Meat and cancer: a relation in search of a mechanism. Lancet . 1999;353(9154):686-687. 36. Fuchs CS, Giovannucci EL, Colditz GA, et al. Dietary fiber and the risk of colorectal cancer and adenoma in women. N Engl J Med . 1999;340(3):169-176. 37. Kunzmann AT, Coleman HG, Huang WY, Cantwell MM, Kitahara CM, Berndt SI. Fruit and vegetable intakes and risk of colorectal cancer and incident and recurrent adenomas in the PLCO cancer screening trial. Int J Cancer . 2016;138(8):1851-1861. 38. Jacobs ET, Lanza E, Alberts DS, et al. Fiber, sex, and colorectal adenoma: results of a pooled analysis. Am J Clin Nutr . 2006;83(2):343- 349. 39. Koushik A, Hunter DJ, Spiegelman D, et al. Fruits, vegetables, and colon cancer risk in a pooled analysis of 14 cohort studies. J Natl Cancer Inst . 2007;99(19):1471-1483. 40. Je Y, Jeon JY, Giovannucci EL, Meyerhardt JA. Association between physical activity and mortality in colorectal cancer: a meta-analysis of prospective cohort studies. Int J Cancer . 2013;133(8):1905-1913. 41. Man J, Zhang T, Yin X, et al. Spatiotemporal trends of colorectal cancer mortality due to low physical activity and high body mass index from 1990 to 2019: a global, regional, and national analysis. Front Med (Lausanne) . 2022;10(8):800426. 42. Meyerhardt JA, Niedzwiecki D, Hollis D, et al. Association of dietary patterns with cancer recurrence and survival in patients with stage III colon cancer. JAMA . 2007;298(7):754-764. 43. Meyerhardt JA, Sato K, Niedzwiecki D, et al. Dietary glycemic load and cancer recurrence and survival in patients with stage III colon cancer: findings from CALGB 89803. J Natl Cancer Inst . 2012;104(22):1702-1711. 44. McCullough ML, Gapstur SM, Shah R, Jacobs EJ, Campbell PT. Association between red and processed meat intake and mortality among colorectal cancer survivors. J Clin Oncol . 2013;31(22):2773-2782. 45. Song M, Nishihara R, Wang M, et al. Plasma 25-hydroxyvitamin D and colorectal cancer risk according to tumour immunity status. Gut . 2016;65(2):296-304. 46. Rigas B, Tsioulias GJ. The evolving role of nonsteroidal anti-inflammatory drugs in colon cancer prevention: a cause for optimism. J Pharmacol Exp Ther . 2015;353(1):2-8. 47. Manson JE, Bassuk SS. Vitamin D research and clinical practice: at a crossroads. JAMA . 2015;313(13):1311-1312. 48. Boghossian S, Hawash A. Chemoprevention in colorectal cancer––where we stand and what we have learned from twenty years’ experience. Surgeon . 2012;10(1):43-52. 49. Benamouzig R, Uzzan B. Identification and chemoprevention in subjects at moderate risk of colorectal cancer. Best Pract Res Clin Gastroenterol . 2011;25(4-5):631-640. 50. Ng K, Meyerhardt JA, Chan AT, et al. Aspirin and COX-2 inhibitor use in patients with stage III colon cancer. J Natl Cancer Inst . 2015;107(1):345. 51. Knights KM, Mangoni AA, Miners JO. Defining the COX inhibitor selectivity of NSAIDs: implications for understanding toxicity. Expert Rev Clin Pharmacol . 2010;3(6):769-776. 52. Chan AT, Arber N, Burn J, et al. Aspirin in the chemoprevention of colorectal neoplasia: an overview. Cancer Prev Res (Phila) . 2012;5(2):164-178. 53. Flossman E, Rothwell M. Effect of aspirin on long-term risk of colorectal cancer: consistent evidence from randomized and observational studies. Lancet . 2007;369(9573):1603-1613. 54. Burn J, Bishop DT, Mecklin JP, et al. Effect of aspirin or resistant starch on colorectal neoplasia in the Lynch syndrome. N Engl J Med . 2008;359(24):2567-2578. 55. Burn J, Gerdes AM, Macrae F, et al. Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial. Lancet . 2011;378(9809):2081-2087. 56. Burn J, Sheth H, Elliott F, et al. Cancer prevention with aspirin in hereditary colorectal cancer (Lynch syndrome), 10-year follow-up and registry-based 20-year data in the CAPP2 study: a double-blind, randomised, placebo-controlled trial. Lancet . 2020;395(10240):1855-1863. 57. Cooper K, Squires H, Carroll C, et al. Chemoprevention of colorectal cancer: systematic review and economic evaluation. Health Technol Assess . 2010;14(32):1-206. 58. Chan AT, Ogino S, Fuchs CS. Aspirin use and survival after diagnosis of colorectal cancer. JAMA . 2009;302(6):649-658. 59. Liao C, Gao F, Cao Y, Tan A, Li X, Wu D. Meta-analysis of the colon J-pouch vs. transverse coloplasty pouch after anterior resection for rectal cancer. Colorectal Dis . 2009;12(7):624-631.
Powered by FlippingBook